Letter on "(1,3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial"

Crit Care. 2021 Feb 9;25(1):55. doi: 10.1186/s13054-020-03450-z.

Authors

Antonios Kritikos¹, Frederic Lamoth¹

Affiliation

¹ Microbiology Institute and Infectious Diseases Service, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011, Lausanne, Switzerland.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antifungal Agents / therapeutic use
Candidiasis, Invasive* / diagnosis
Candidiasis, Invasive* / drug therapy
Glucans
Humans
Proteoglycans
beta-Glucans*

Substances

Antifungal Agents
Glucans
Proteoglycans
beta-Glucans
polysaccharide-K